已发表论文

预防左炔诺孕酮宫内缓释系统在子宫腺肌病中脱落的叙事性综述与风险分层框架

 

Authors Zhao J, Chen J, Wang X, Wang H

Received 11 September 2025

Accepted for publication 21 December 2025

Published 8 January 2026 Volume 2026:22 566786

DOI https://doi.org/10.2147/TCRM.S566786

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor De Yun Wang

Jin Zhao,* Jianliang Chen,* Xiaoe Wang,* Huabin Wang* 

Department of Obstetrics and Gynecology, the First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Huabin Wang, Department of Obstetrics and Gynecology, the First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang, People’s Republic of China, Email genical@sina.com
摘要 目的:左炔诺孕酮宫内缓释系统在子宫腺肌病患者中的脱落率(15-37.5%)显著高于子宫正常女性(3-10%),严重影响治疗效果和患者依从性。目前关于其风险因素与防控策略的证据较为分散,缺乏系统的管理框架。本文旨在通过叙事性综述,整合现有证据,构建一个针对性的风险分层管理模型。 方法:综述综合分析了当前文献,系统识别了导致LNG-IUS脱落的关键风险因素,包括子宫体积增大、宫腔内病变以及放置技术等;同时评估了诸如促性腺激素释放激素激动剂预处理、影像学引导下放置等预防策略的有效性。 结果:基于解剖结构、操作技术和临床特征等多重因素,本文提出了一个全新的三级风险分层模型。该模型为不同风险级别的患者个体化推荐管理策略:常规放置、强化预处理(如GnRH-a)或高级固定技术。 结论:所提出的结构化风险分层框架,有助于优化LNG-IUS在子宫腺肌病患者中的留存率,并实现医疗资源的合理配置。未来仍需通过随机对照试验进行前瞻性验证,以确立基于循证医学的个体化治疗规范。

关键词:左炔诺孕酮宫内缓释系统;子宫增大;宫内节育器移位;促性腺激素释放激素激动剂;超声检查;治疗有效性